Butterfly's chip ships inside Mendaera's robot while insiders sold $31.95 million
Mendaera's Focalist robot became the first Butterfly Embedded product to reach market on 1 October 2026, the licensing thesis's first commercial test. Insiders sold $31.95 million of BFLY in the three months before it arrived.
Vincent Jiangthree-minute read
Mendaera's FDA-cleared Focalist robot, a handheld system for guiding needles in vascular access, nerve blocks and organ access, went commercially available with a customized Butterfly−8.55% — Butterfly, down 8.55 percent today iQ3 probe on 1 October 1. Butterfly calls Mendaera the first Butterfly Embedded partner to commercialize, which makes this week the first time the licensing thesis has a product on a shelf 1. No financial terms were disclosed.
The rest of the pipeline sits earlier. Merge Labs, launched in January with $252 million from investors including OpenAI$1.18T — OpenAI, private, latest valuation $1.18T, Bain Capital and Gabe Newell and with Sam Altman on its founding team, is building brain-computer interfaces on the chip 2. Its multi-year licence pays Butterfly upfronts, milestones and technology-access fees; royalties are only "expected" 2. The Midjourney Medical full-body imaging build has not shipped 3.
Embedded already books revenue, $5.7 million in the first quarter, up 147%, driven primarily by Midjourney 4. That is development money. The royalties the street is underwriting start with a robot that holds needles.
The ledger beside the launch
Insiders sold 4,708,246 shares for $31,950,688 in the three months to early October 5. Director Jonathan Rothberg cut his stake 95.67%, selling 1,195,857 shares at $6.60 under a pre-arranged 10b5-1 plan, and another insider's sale covered tax withholding 5. One director swam the other way: Louise Phanstiel bought 115,200 shares at $8.68 on 14 August, $999,936 in total 6. Plan sales and tax sales are mechanical. The direction is still one-way.
$31.95 million out, $1.0 million in
Data
| Value | |
|---|---|
| Insiders sold, total | $31.95M |
| Jonathan Rothberg sold | $7.89M |
| Louise Phanstiel bought | $1M |
The street pays for the chip, not the royalties
Q2 revenue of $32.61 million beat the $29.16 million consensus and cleared the top of management's own $27 million to $31 million guide, with gross margin up to 71.4% from 63.7% and the quarterly adjusted EBITDA loss narrowed to $1.4 million from $6.2 million 543. The full year still carries a guided $19 million to $23 million adjusted EBITDA loss against $124.7 million of June cash, at a $2.38 billion market cap 357.
Ten quarters of growth, and the first licensed product only now ships
Data
| Revenue | |
|---|---|
| Q1 '24 | $17.66M |
| Q2 '24 | $21.49M |
| Q3 '24 | $20.56M |
| Q4 '24 | $22.35M |
| Q1 '25 | $21.23M |
| Q2 '25 | $23.38M |
| Q3 '25 | $21.49M |
| Q4 '25 | $31.51M |
| Q1 '26 | $26.53M |
| Q2 '26 | $32.61M |
Needham's 22 September initiation drove a 22% single-day move to $9.93 3. Evercore−4.80% — Evercore, down 4.80 percent today followed on 29 September with $15 against an $8.54 consensus; TD Cowen and Needham sit at $10, and Weiss Ratings still carries a "sell (d-)" from 3 August 65. The stock gapped from a $9.15 close to a $9.69 open on 29 September and last traded at $9.54, inside a one-year range of $1.87 to $10.05 65.
Evercore's $15 stands alone above a consensus that trails the tape
- Estimate
Data
| Value | |
|---|---|
| Evercore, 29 Sep (estimate) | $15 |
| Needham, 22 Sep (estimate) | $10 |
| TD Cowen, 11 Sep (estimate) | $10 |
| 29 Sep last trade | $9.54 |
| Consensus (estimate) | $8.54 |
The counter and the tell
Institutions lean in: 33 hedge funds held the stock in the second quarter against 26 a quarter earlier, and BlackRock−2.44% — BlackRock, down 2.44 percent today added about 17.9% to its position 8. The short side is sizeable too: 32.18 million shares, about 15% of the float, were sold short at the 14 August settlement 8. One columnist's line on the unshipped half of the story, "R&D burn dressed up as a platform", names the standing risk: GE, Philips and Siemens own the installed bases 7. Both companies demo at ACEP26 in Chicago, 5 to 7 October 1.
The tell is the first disclosed per-unit royalty from a partner's shipping product. The margins prove the chip. The register has yet to prove the business.
Get Health by email, free
AI in medicine, pharma and biotech. In our daily email, every weekday.

Reader comments
0 comments